New research helps explain why infection with herpes simplex virus-2 (HSV-2), which causes genital herpes, increases the risk for HIV infection even after successful treatment heals the genital skin ...

– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, ...

(Reuters) - BioNtech has dosed the first patient with its BNT163 herpes vaccine candidate designed to prevent genital lesions as part of a first-in-human Phase 1 clinical research study, the German ...

Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...

People with genital herpes can transmit the virus to partners even when they do not have lesions, new research shows. This has been suspected before, but "the data here looks really robust," said Fred ...

January 27, 2010 — Herpes simplex virus type 2 (HSV-2) can regularly reactivate throughout the genital tract, a finding that may affect treatment and prevention, according to a study published online ...

Variation at HLA and KIR loci is associated with the severity of viral infections. To assess associations of genital HSV-2 infection with human HLA and KIR genetic loci, we measured the frequencies of ...

It's possible for oral herpes to cause genital herpes and vice versa Medically reviewed by Steffini Stalos, DO Genital herpes can be caused by HSV-1, commonly known as the virus causing cold sores.

Herpes simplex virus type 1 (HSV-1) most commonly causes cold sores while HSV-2 is associated with genital herpes. But, it’s also possible to contract an HSV-2 infection in the mouth from sex without ...

First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine ...

– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo ...